Edgewise Therapeutics, Inc.
EWTXHeld by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase2 readout (EDG-7500): Jun 2026. Short interest: 13.3% of float.
Held by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase2 readout (EDG-7500): Jun 2026. Short interest: 13.3% of float.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.